OpenNashEarnings

Becton Dickinson (BDX) · Medical Devices

Becton Dickinson Q3 FY2026 earnings: summary, key numbers & outlook

Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

BD's first full quarter as a focused MedTech company showed broad growth across all four segments, led by BioPharma Systems' GLP-1 injection pen collaboration in Brazil and Interventional's new laser launch.

BD completed its separation of the Biosciences and Diagnostic Solutions business into Waters in February, and this was its first full quarter as 'New BD' with four segments. All four grew. Advanced Patient Monitoring was the fastest-growing unit, and U.S. sales outpaced international. Product news included a Vizient Innovative Technology contract for the CentroVena One insertion system, the Elyra Thulium Fiber Laser System for kidney stone care, and an EMS semaglutide launch in Brazil on BD's Vystra Injection Pen.

Management is steering toward a simpler, more focused company built around key growth platforms, under its 'Excellence Unleashed' strategy. It has exited operational activities and projects that no longer fit, taking $450 million of non-cash impairment charges over nine months. The main risks are the Alaris infusion system's timing for return to market in the U.S., tariffs, Middle East supply disruption, and changes in U.S. vaccine and pharmaceutical policy that could reduce demand.

Key numbers

Revenue · GAAP
$5.0B

up 5.4% reported, 4.4% FXN

Diluted EPS from continuing operations · GAAP
$1.64

up 4.5% from a year ago

Adjusted diluted EPS from continuing operations · non-GAAP
$3.23

up 4.9% from a year ago

Net income from continuing operations · GAAP
$451.0M

flat (up 0.1%) from a year ago

Operating income · GAAP
663.0M

down 10.3% from a year ago

Nine-month cash from continuing operations · GAAP
$2.1 billion

up 33.3% year to date

Nine-month free cash flow · non-GAAP
$1.7 billion

up 44.6% year to date

Segment or metricValueChange
Medical Essentials$1.7Bup 4.5% reported, 3.2% FXN
Connected Care$1.2Bup 4.9% reported, 4.4% FXN
BioPharma Systems$670.0Mup 6.6% reported, 5.2% FXN
Interventional$1.4Bup 6.4% reported, 5.5% FXN
Advanced Patient Monitoring$309.0Mup 10.9% reported, 11.2% FXN
Specimen Management$511.0Mup 8.7% reported, 7.0% FXN
Peripheral Intervention$552.0Mup 7.8% reported, 6.1% FXN
Where each number comes from
  • Revenue: “Revenues | $4,983 | $4,726 | 5.4% | 4.4% Reported Diluted Earnings per Share | $1.64 | $1.57 | 4.5% | 3.8%”
  • Diluted EPS from continuing operations: “Reported Diluted Earnings per Share | $1.64 | $1.57 | 4.5% | 3.8% Adjusted Diluted Earnings per Share1 | $3.23 | $3.08 | 4.9% | 3.9%”
  • Adjusted diluted EPS from continuing operations: “Adjusted Diluted Earnings per Share1 | $3.23 | $3.08 | 4.9% | 3.9% 1Represents a non-GAAP financial measure; refer to reconciliations”
  • Net income from continuing operations: “Income tax provision | 102 | 118 | (13.2) Net Income from Continuing Operations | 451 | 451 | 0.1 (Loss) Income from Discontinued Operations, Net of Tax”
  • Operating income: “Total Operating Costs and Expenses | 4,320 | 3,986 | 8.4 Operating Income | 663 | 739 | (10.3) Interest expense | (132) | (152) | (13.4)”
  • Nine-month cash from continuing operations: “Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion”
  • Nine-month free cash flow: “Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion”
  • Medical Essentials: “Medical Essentials2 | $1,675 | $1,602 | 4.5% | 3.2% Connected Care2 | $1,224 | $1,166 | 4.9% | 4.4%”
  • Connected Care: “Connected Care2 | $1,224 | $1,166 | 4.9% | 4.4% BioPharma Systems2 | $670 | $629 | 6.6% | 5.2%”
  • BioPharma Systems: “BioPharma Systems2 | $670 | $629 | 6.6% | 5.2% Interventional2 | $1,414 | $1,328 | 6.4% | 5.5%”
  • Interventional: “Interventional2 | $1,414 | $1,328 | 6.4% | 5.5% Total Revenues | $4,983 | $4,726 | 5.4% | 4.4%”
  • Advanced Patient Monitoring: “Advanced Patient Monitoring | 189 | 176 | 7.4 | 120 | 102 | (1) | 17.1 | 17.8 | 309 | 278 | (1) | 10.9 | 11.2”
  • Specimen Management: “Specimen Management | 274 | 240 | 14.0 | 237 | 230 | 8 | 3.1 | (0.2) | 511 | 470 | 8 | 8.7 | 7.0”
  • Peripheral Intervention: “Peripheral Intervention | $294 | $271 | 8.4 | $258 | $241 | $9 | 7.2 | 3.5 | $552 | $512 | $9 | 7.8 | 6.1”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 FY2026vs year agovs last quarter
Revenue$5.0B+5.4%+5.7%
Operating income$663.0M−10.3%+612.9%
Net income$377.0M−34.3%—
Diluted EPS$1.37−31.5%—
Operating margin13.3%−2.3 pts+11.3 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted diluted EPSfiscal 2026$12.62 to $12.72

Key takeaways

  1. First full quarter as focused 'New BD'

    Following the February spin-off and combination with Waters, BD operates four segments and said the quarter showed early benefits of a more focused MedTech company. All four segments grew.

  2. BioPharma Systems tied to GLP-1 self-injection

    BD announced a collaboration with EMS, a leading Brazilian pharmaceutical company, to launch semaglutide using BD's Vystra Injection Pen platform. It extends BD's role in access to obesity and type 2 diabetes therapies.

  3. Interventional expanded kidney stone portfolio

    BD launched the Elyra Thulium Fiber Laser System, designed to improve efficiency, versatility and workflow for urology teams. Interventional also grew 6.4% as reported.

  4. Vizient award validates CentroVena One

    The BD CentroVena One Insertion System won a Vizient Innovative Technology contract. BD describes it as designed to simplify central line insertion and improve patient and clinician safety.

  5. Portfolio pruning under Excellence Unleashed

    BD recorded $450 million of non-cash impairments to exit activities and projects no longer aligned with its strategy. The goal is simpler operations and resources behind its most value-creating platforms.

Charts

Revenue$5.0B+5.4% y/yQ3 FY26
Q4 FY24: $5.4B (worked out from the annual figure)Q4 24$5.4BQ1 FY25: $5.2BQ1 25$5.2BQ2 FY25: $4.5BQ2 25$4.5BQ3 FY25: $4.7BQ3 25$4.7BQ4 FY25: $8.3B (worked out from the annual figure)Q4 25$8.3BQ1 FY26: $5.3BQ1 26$5.3BQ2 FY26: $4.7BQ2 26$4.7BQ3 FY26: $5.0BQ3 26$5.0B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$5.4B *
Q1 FY25$5.2B
Q2 FY25$4.5B
Q3 FY25$4.7B
Q4 FY25$8.3B *
Q1 FY26$5.3B
Q2 FY26$4.7B
Q3 FY26$5.0B
Diluted EPS (GAAP)$1.37−31.5% y/yQ3 FY26
Q1 FY25: $1.04Q1 25$1.04Q2 FY25: $1.07Q2 25$1.07Q3 FY25: $2.00Q3 25$2.00Q1 FY26: $1.34Q1 26$1.34Q2 FY26: -$1.11Q2 26-$1.11Q3 FY26: $1.37Q3 26$1.37
Data
Q1 FY25$1.04
Q2 FY25$1.07
Q3 FY25$2.00
Q1 FY26$1.34
Q2 FY26-$1.11
Q3 FY26$1.37

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin13.3%−2.3 pts y/yQ3 FY26
Q4 FY24: 11.4%Q4 2411.4%Q1 FY25: 8.8%Q1 258.8%Q2 FY25: 8.5%Q2 258.5%Q3 FY25: 15.6%Q3 2515.6%Q4 FY25: 14.1%Q4 2514.1%Q1 FY26: 10.5%Q1 2610.5%Q2 FY26: 2.0%Q2 262.0%Q3 FY26: 13.3%Q3 2613.3%
Data
Q4 FY2411.4%
Q1 FY258.8%
Q2 FY258.5%
Q3 FY2515.6%
Q4 FY2514.1%
Q1 FY2610.5%
Q2 FY262.0%
Q3 FY2613.3%
Free cash flow$549.0M−6.6% y/yQ1 FY26
Q1 FY25: $588.0MQ1 25$588.0MQ1 FY26: $549.0MQ1 26$549.0M
Data
Q1 FY25$588.0M
Q1 FY26$549.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What did BD launch or announce in Q3 FY2026?

BD launched the Elyra Thulium Fiber Laser System for kidney stone care, won a Vizient Innovative Technology contract for CentroVena One, and announced an EMS collaboration for a semaglutide launch in Brazil using the Vystra Injection Pen platform.

What is BD's strategy after the Waters transaction?

BD, now called New BD, is a more focused MedTech company with four segments, concentrating on key growth platforms, innovation and BD Excellence under its Excellence Unleashed strategy.

Which BD businesses grew fastest this quarter?

Advanced Patient Monitoring grew 10.9% reported and Specimen Management 8.7%. Among segments, BioPharma Systems rose 6.6% and Interventional 6.4%.

How is BD participating in the GLP-1 market?

Through a collaboration with EMS in Brazil, whose semaglutide launch will use BD's Vystra Injection Pen platform for self-injection by patients with obesity and type 2 diabetes.

What are the main risks BD flags for its plan?

BD cites tariffs, Middle East supply chain disruption, U.S. policy changes affecting vaccines and pharmaceuticals, and the timing of the Alaris infusion system's return to market in the U.S.

Documents

SEC filing